CompletedNot Applicable

ESWT as a Treatment for Chronic NHO in TBI Patients

Israel12 participantsStarted 2014-10

Plain-language summary

Effect of Extracorporeal Shock Wave Therapy on Chronic Neurogenic Heterotopic Ossification in Traumatic Brain Injured (TBI) patients Chronic Neurogenic Heterotopic Ossification (NHO) - Heterotopic ossification is a well known late complication of traumatic brain injury. Extracorporeal Shock Wave Therapy - ESWT- is used in various medical situations and is being tested for feasibility of use in TBI patients.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> 18 years * Brain injured patients with a diagnosis of NHO around the hip and/ or knee for a period of greater than one year. * Patients who are able, or legal guardians who are willing, to provide informed consent after both oral and written information. Exclusion Criteria: * Pregnancy. * Rheumatoid arthritis, ankylosing spondylitis, or femoral neck fractures * Elevated serum alkaline phosphatase (SAP) levels and/or evidence of active bone remodelling in bone scan

What they're measuring

Change in Visual Analogue Scale (VAS) from baseline to final assessment

Timeframe: VAS will be assessed at two weekly intervals from week 0 (Baseline) until week 22, at week 26 and at week 38.

Trial details

NCT IDNCT02331628

SponsorLoewenstein Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-09-13

View on ClinicalTrials.gov More TBI Traumatic Brain Injury trials